1. Schweizerische Alzheimervereinigung. Priorität Demenz-116000 Menschen mit Demenz in der Schweiz. alzheimer. 2014.
2. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137–52.
3. Biétry F, Schur N, Pfeil A, et al. Helsana Arzneimittelreport. 2015. 1–200.
4. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA. 2015;72(2):136–42.
5. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology. The Anatomical Therapeutic Chemical (ATC) and defined daily dosing (DDD) system. http://www.whocc.no/atcddd/ . Accessed 27 Jun 2014.